Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42 (market cap $3.80B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is far larger — about 3.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 96 Days on average.
| MRVI | VNQI | |
|---|---|---|
Market Cap | $972.90M | $3.80B |
Volume | 4,325,710 | 274,816 |
Sector | Health | — |
52-Week High | $9.00 | $50.76 |
52-Week Low | $2.83 | $41.81 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VNQI trades at $42.04, up 0.14% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF focuses on international real estate outside the U.S., offering diversification across more than 30 countries and a competitive expense ratio of 0.12%. Recent news highlights a significant drop in short interest in September 2026, suggesting reduced bearish speculation, while comparisons with peers emphasize its higher dividend yield.
The outlook remains cautious due to global real estate market volatility and bearish technicals, though reduced short interest and international exposure present opportunities for yield-seeking investors. Risks include currency fluctuations and economic downturns in foreign markets, requiring careful monitoring of macroeconomic trends for potential recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →